Copeland Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Copeland Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-12,584	Closed	-$456K	–	140
2016 Q4	$456K	Sell	12,584 -7,474	-37%	-$298K	0.03%	128
2016 Q3	$923K	Sell	20,058 -42,326	-68%	-$2.21M	0.06%	125
2016 Q2	$3.13M	Buy	62,384 +2,490	+4%	+$133K	0.22%	102
2016 Q1	$3.21M	Buy	59,894 +19,450	+48%	+$1.14M	0.22%	102
2015 Q4	$2.65M	Sell	40,444 -334,734	-89%	-$20.7M	0.15%	113
2015 Q3	$21.2M	Buy	375,178 +104,955	+39%	+$6.81M	1.3%	27
2015 Q2	$16M	Buy	270,223 +12,534	+5%	+$773K	0.82%	53
2015 Q1	$16.1M	Sell	257,689 -1,588	-0.6%	-$92.3K	1.07%	38
2014 Q4	$14.9M	Buy	259,277 +232,547	+870%	+$13M	1.08%	45
2014 Q3	$1.44M	Buy	26,730 +2,601	+11%	+$138K	0.15%	63
2014 Q2	$1.26M	Buy	24,129 +7,259	+43%	+$371K	0.14%	66
2014 Q1	$891K	Buy	16,870 +4,537	+37%	+$210K	0.11%	78
2013 Q4	$494K	Buy	+12,333	New	+$486K	0.06%	90

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Copeland Capital Management's TEVA Position: Q1 2017 in Review

Copeland Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2017, closing a stake of 12,584 shares — an estimated $456K sold.

Copeland Capital Management first reported a position in TEVA in Q4 2013 and held it in 13 quarters. The position peaked at $21.2M in Q3 2015. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Copeland Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2017 after selling out during the quarter.
Copeland Capital Management sold 12,584 Teva Pharmaceutical Industries Limited shares in Q1 2017, an estimated $456K.
Copeland Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2013 and held it in 13 quarters.
Copeland Capital Management's Teva Pharmaceutical Industries Limited position peaked at $21.2M in Q3 2015.
688 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2017.

Based on Copeland Capital Management's 13F filing for Q1 2017, filed 2 May 2017.